Opinion|Videos|January 2, 2026
RWO 1L lupatercept vs 2L ESA
Explore real-world outcomes of Luspatercept and second-line ESAs in treating low-risk MDS, revealing promising response rates and treatment insights.
Advertisement
Episodes in this series
Advertisement
Related to this article
Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.
Ursula A. Matulonis, MD, surveyed the exploitable genetic changes driving the next wave of ovarian cancer trials, from CDK2 and WEE1 inhibitors to PARG inhibitors.
Ursula A. Matulonis, MD, broke down the trial design, backbone regimen, and preclinical rationale that she believes made KEYNOTE-B96 a positive study.
Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.
Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and sexual health.
Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
Advertisement
Advertisement
Trending on CancerNetwork
1
Acid Reducers, Drug-Drug Interactions, and Setting Expectations for Response
2
How Psycho-Oncology Addresses Existential Distress, Body Image, and Intimacy
3
Differentiation Syndrome, Cardiac Monitoring, and Administration of Menin Inhibitors
4
Meaning-Centered Therapy, Psychiatry Referrals, and Humanistic Cancer Care
5